MDWD

MediWound Ltd. [MDWD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MDWD Stock Summary

Top 10 Correlated ETFs

MDWD

Top 10 Correlated Stocks

MDWD

In the News

MDWD Financial details

Company Rating
-
Market Cap
151.77M
Income
-6.72M
Revenue
18.69M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
100
Optionable
No
Shortable
Yes
Earnings
28 May 2024
P/E
-9.26
Forward P/E
-
PEG
1.15
P/S
4.61
P/B
3.48
P/C
-
P/FCF
-11.19
Quick Ratio
5.88
Current Ratio
6.31
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-80.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-10.08%
Revenue Q/Q
11.77%
EPS Q/Q
-20.83%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-14.29%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-44%
ROC
-0.16%
Gross Margin
44%
Oper. Margin
-38%
Profit Margin
-50%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.1-17.25
52W High
+8.47%
52W Low
+163.43%
RSI
52
Rel Volume
0.67
Avg Volume
66.21K
Volume
44.52K
Perf Week
0%
Perf Month
3.25%
Perf Quarter
-5.1%
Perf Half Y
6.9%
-
-
-
-
Beta
0.926
-
-
Volatility
0.14%, 0.61%
Prev Close
0.6%
Price
18.44
Change
-0.49%

Something similar

Top by Market Cap
AMZ.DE
VTSAX
LLY
MSFT
ABEC.DE
Top Correlated ETFs
DGP
IGLD
GLD
IAU
OUNZ
Top Correlated Stocks
ASMB
RYTM
COBR.L
QSI
HCMAU
Similar Market Cap
EXD
1613.HK
HSP.L
PVIVX
ASPO.HE

Company Profile

Healthcare Biotechnology
  • Volume Average 66.21K
  • Market Capitalization 151.77M
  • Employee 100
  • CEO Mr. Ofer Gonen B.Sc.
  • Headquarters Yavne,IL
  • IPO Date 2014-03-20
  • Website https://www.mediwound.com

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.